First mRNA flu vaccine wins FDA approval. A quiet revolution for pandemic preparedness

For more than seven decades, the world has made flu shots the slow way. Grow the virus in chicken eggs. Pick the strains roughly nine months before the season. Hope the guess holds. On 5 August 2026, the US Food and Drug Administration approved mFLUSIVA (also known as mRNA-1010), Moderna's messenger RNA seasonal influenza vaccine for adults aged 50 and older. It is the first flu vaccine ever licensed in the United States that is built on the mRNA platform, and the first to be approved anywhere in the world. The label is narrow. The implications are not.

What happened?#

Moderna's BLA (Biologics License Application) was filed in December 2025, and the FDA's decision landed on the day the agency's PDUFA target action date expired. The agency used two regulatory pathways in one decision: a traditional approval for adults aged 50 to 64, and an accelerated approval for adults aged 65 and older, contingent on a confirmatory postmarketing study.

The traditional approval rests on the FLUENT Phase 3 trial (NCT06602024), which enrolled 40,805 adults across 11 countries. Roughly half received a single 0.5 mL dose of mFLUSIVA; the others received a licensed standard-dose comparator. mFLUSIVA reduced the risk of RT-PCR-confirmed, protocol-defined influenza-like illness by 26.6% (95% CI 16.7 to 35.4) compared with the comparator, meeting the pre-specified superiority threshold. Efficacy held up across strains: 29.6% against A/H1N1, 22.2% against A/H3N2 and 29.1% against B/Victoria. The accelerated approval for the over-65 cohort drew on a separate immunogenicity study (NCT05827978) and will be confirmed in a pragmatic head-to-head trial against a high-dose vaccine starting in August 2026.

The safety profile was acceptable. No new safety signals were identified; serious adverse events were balanced between arms (2.2% versus 1.9%); and no cases of myocarditis or pericarditis were reported. Solicited reactions, injection-site pain, fatigue, headache, myalgia, were mostly mild to moderate and resolved within a day or two, consistent with the known reactogenicity of mRNA COVID-19 vaccines.

Moderna says initial doses will reach US retailers within weeks, with broader availability for the 2026–2027 respiratory virus season. Reviews are also underway in the European Union, Canada and Australia.

A faster way to make an old vaccine#

Influenza is a deceptive enemy. The virus's surface protein, haemagglutinin, drifts continuously, which is why seasonal vaccines have to be reformulated each year. Most of the world's flu doses are still made by inoculating embryonated chicken eggs with candidate strains, letting them replicate for weeks, then harvesting, inactivating and purifying the virus. The approach is mature, cheap and famously slow. Manufacturers need the WHO's strain recommendations roughly nine months ahead of the northern-hemisphere flu season to seed production in time.

mRNA vaccines invert that workflow. Instead of growing virus, manufacturers synthesise a lipid nanoparticle containing mRNA that codes for the haemagglutinin of each target subtype. The recipient's own cells then make the protein, train the immune system, and the manufacturing process itself barely changes when the sequence does. Once the platform is set up, swapping in a new strain is closer to editing a file than retooling a factory. During COVID-19, Moderna produced a first batch of its vaccine within a month of the SARS-CoV-2 sequence being published.

This matters because influenza is the pathogen most likely to cause the next pandemic. The current H5N1 panzootic, the largest avian-influenza event on record, is now circulating in wild birds across all six Australian states, with 186 confirmed H5 detection events and the federal government warning that nearly 400 native species including penguins, sea lions, seals and the Tasmanian devil are at risk. The H5N1 strain circulating in dairy cattle in the United States has caused 71 confirmed human cases and two deaths since 2024. None of those infections has yet triggered sustained human-to-human transmission, but every spillover is another roll of the dice.

That backdrop is what the WHO and partners had in mind when they launched the 100 Days Mission, which aims to deliver a safe, effective vaccine against any pandemic threat within roughly 100 days of pathogen identification. Until this month, the only mRNA vaccines with full regulatory approval anywhere targeted SARS-CoV-2.

Why this matters#

For pandemic preparedness, the practical consequence of an mRNA flu approval is the ability to make late decisions. If a new H5N1 variant emerges next spring, manufacturers can in principle update the antigen sequence and start producing doses within weeks rather than waiting on six months of egg-based growth. That window is the difference between containing a spark and containing a wildfire.

The approval also opens the door to combination products. Moderna is already running late-stage trials of an mRNA COVID-plus-influenza combination, and the same lipid-nanoparticle backbone that carries flu haemagglutinin can carry other antigens. Each approved mRNA indication lowers the regulatory and manufacturing friction for the next one.

For seasonal flu, the immediate payoff is sharper strain selection. Public health agencies have long known that egg-adapted mutations can blunt vaccine effectiveness against circulating H3N2. mRNA production sidesteps that problem, which is a quiet but meaningful upgrade to the tools we already have.

Critical analysis#

The 26.6% relative-efficacy figure is real but modest. Seasonal flu vaccines have rarely topped 50% relative efficacy even in good years, and mFLUSIVA's improvement over a standard-dose comparator is statistically robust without being transformative. The postmarketing study, which compares the vaccine to a high-dose competitor in over-65s, will determine whether the accelerated approval converts to a full one.

There are also open questions the Phase 3 data do not resolve. How durable is protection across a full season? Will the platform match the high-dose vaccine in frail elderly recipients, who generate weaker immune responses to standard vaccines? What does year-on-year reformulation look like when the antigen sequence changes is there any risk of imprinting, where the immune system clings to the first flu variant it ever saw? And on the supply side, mRNA manufacturing still depends on a constrained set of lipid-nanoparticle inputs that limit how fast output can be scaled.

Competing approaches remain in the race. Sanofi, GSK, CSL Seqirus and others are betting on recombinant protein and adjuvanted platforms that promise broader, longer-lasting protection without the cold-chain demands of mRNA. Researchers at the University of Cambridge and DIOSynVax recently reported the first human data for an AI-designed universal coronavirus vaccine. None of these platforms is mutually exclusive, and the world will likely run several in parallel, which is exactly what the 100 Days Mission requires.

Expert perspective#

When Moderna's mRNA-1273 entered clinical trials in March 2020, it was the first time a vaccine based on the platform reached a human in response to a pandemic pathogen. mFLUSIVA is the first time the platform has won approval for an endemic disease that, under the right conditions, becomes a pandemic one. That distinction matters more than the modest 26.6% efficacy figure might suggest.

The COVID-19 mRNA vaccines were an emergency proof of concept, scaled under wartime conditions. mFLUSIVA is a regulated, commercially-available product that has cleared the same kind of Phase 3 trial required of any new flu shot, with the added wrinkle of a platform the FDA had not previously licensed. The experience of running that trial, 40,000 participants, 11 countries, a strain update between seasons, is itself part of the regulatory familiarity that future pandemic mRNA vaccines will inherit.

It is not a universal flu vaccine. The DIOSynVax candidate and others aim to teach the immune system to recognise conserved parts of the virus that do not drift. mFLUSIVA still targets the drifting parts. But a platform that can be reformulated quickly is a different kind of insurance policy: less a single shield than a forge.

Key takeaways#

1. The FDA approved the world's first mRNA seasonal flu vaccine on 5 August 2026, mFLUSIVA from Moderna, for adults aged 50 and older.
2. The pivotal Phase 3 trial enrolled 40,805 participants across 11 countries and showed 26.6% better protection than a standard-dose comparator.
3. mRNA production is sequence-flexible: the same factory can switch strains in weeks, instead of the nine months that egg-based production needs.
4. This is direct support for the WHO 100 Days Mission for pandemic vaccines, especially against H5N1, which is currently spreading in wild birds across six Australian states and has caused 71 human cases in the United States.
5. The full benefit will take time: the over-65 indication is on an accelerated approval, durability data are still being collected, and a confirmatory head-to-head trial against a high-dose vaccine begins later this month.

Frequently asked questions#

Is mFLUSIVA different from a COVID-19 mRNA vaccine? It uses the same lipid-nanoparticle platform but encodes three haemagglutinin proteins (H1N1, H3N2, B/Victoria) instead of the SARS-CoV-2 spike. The dose is 37.5 micrograms of total mRNA, split three ways.

Who can get it right now? Adults aged 50 and older in the United States. Adults 65 and older fall under an accelerated approval pending a confirmatory postmarketing study.

Does it protect against H5N1 bird flu? Not directly. mFLUSIVA targets the seasonal H1N1, H3N2 and B/Victoria strains. The relevance to H5N1 is the platform: the same manufacturing process can in principle be retooled for a pandemic H5 strain in weeks rather than months.

Why only 26.6% better than the comparator? is that good? For a seasonal flu vaccine, yes. Effectiveness varies year to year depending on strain match, and most licensed flu shots hover in the 20–60% range. mFLUSIVA met its pre-specified superiority threshold against a standard-dose comparator, which was the regulatory bar.

When will the over-65 confirmation come? Moderna has agreed to a pragmatic, randomised head-to-head study (mRNA-1010-P910) against a high-dose comparator, with study initiation scheduled for 31 August 2026.

What about combination products? Moderna has reported late-stage data for mRNA-1083, a COVID-plus-influenza combination using the same backbone. Approval of mFLUSIVA removes a major regulatory and manufacturing hurdle for that pipeline.

Are there any safety concerns? No new safety signals were identified in the Phase 3 programme. As with other mRNA vaccines, transient reactogenicity, fatigue, muscle aches, injection-site pain is more common than with standard flu shots. No myocarditis or pericarditis cases were reported in the 40,805-participant trial.

When can I get one? Moderna expects doses at selected US retailers within weeks of approval, with broader availability through the 2026–2027 northern-hemisphere respiratory virus season.

References#

1. US Food and Drug Administration. Approval Letter: Influenza Vaccine, mRNA (MFLUSIVA), 5 August 2026. https://www.fda.gov/media/194121/download?attachment
2. US Food and Drug Administration. Clinical Review: mFlusiva, 5 August 2026. https://www.fda.gov/media/194140/download
3. Moderna, Inc. Moderna receives U.S. FDA approval for influenza vaccine mFLUSIVA (mRNA-1010), 6 August 2026. https://www.drugs.com/newdrugs/fda-approves-mflusiva-influenza-vaccine-mrna-prevention-seasonal-influenza-6855.html
4. BioPharma Dive. FDA approves Moderna's mRNA flu vaccine, 5 August 2026. https://www.biopharmadive.com/news/moderna-fda-approve-mflusiva-seasonal-influenza/826864/
5. AJMC. FDA Approves Moderna's mRNA Flu Vaccine After Phase 3 Success, 6 August 2026. https://www.ajmc.com/view/fda-approves-moderna-s-mrna-flu-vaccine-after-phase-3-success
6. Pharmaceutical Executive. FDA Approves Moderna's mRNA-Based Flu Vaccine, August 2026. https://www.pharmexec.com/view/fda-moderna-mrna-based-flu-vaccine
7. STAT News. FDA approves Moderna's mRNA flu vaccine, the first to use the technology, 5 August 2026. https://www.statnews.com/2026/08/05/fda-approves-moderna-mflusiva-first-mrna-flu-vaccine/
8. Nature Reviews Microbiology / PMC. Message in a bottle: mRNA vaccination for influenza. https://pmc.ncbi.nlm.nih.gov/articles/PMC10027004/
9. Vaccines / PMC. Advantages of Broad-Spectrum Influenza mRNA Vaccines and Their Combined Effects. https://pmc.ncbi.nlm.nih.gov/articles/PMC11680418/
10. mRNA and Next-Generation Vaccine Platforms for Pandemic Influenza Preparedness, expert perspective, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC13029868/
11. World Health Organization. Avian influenza A(H5N1) virus situation page, updated July 2026. https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-a-h5n1-virus
12. US Centers for Disease Control and Prevention. Global Summary of Human Cases of H5N1 Bird Flu, 26 June 2026. https://www.cdc.gov/bird-flu/spotlights/global-summary-06262026.html
13. Australian Department of Agriculture, Fisheries and Forestry. Bird flu (avian influenza) campaign page, data current to 13 August 2026. https://www.agriculture.gov.au/campaigns/birdflu
14. ScienceDaily. AI-designed universal coronavirus vaccine passes first human trial, June 2026. https://www.sciencedaily.com/releases/2026/06/260605023357.htm

All trial results and regulatory decisions cited are from primary or official sources.